March 23, 2020

Nomination Committee proposes Torben Jørgensen for new chairman of Genovis

Regulatory
Genovis’ Nomination Committee proposes new election of Torben Jørgensen to serve on the Board of Directors and as Chairman of the Board at the Annual General Meeting on May 5.

 

Torben Jørgensen was born in 1952 and is currently Chairman of the Board of Biotage AB and Atlas Antibodies AB. He also serves on the boards of Micropos AB and Intervacc AB. Previous appointments include CEO and President of Biotage AB from 2006 to 2020, Affibody AB from 2001 to 2005, Karo Bio from 2000 to 2001 and DAKO AB from 1988 to 1999.

 

“The Nomination Committee is pleased to be able to propose Torben Jørgensen to serve as the new Chairman of the Board. Torben’s knowledge and experience will be able to contribute to Genovis’ continued progress and growth. At the same time, we would like to warmly thank Sarah Fredriksson for her extremely valuable contribution as she stepped in on short notice to serve as the Chair at a time when Genovis faced a number of important decisions,” says Nomination Committee Chair Mikael Lönn.

 

Furthermore, the Nomination Committee proposes the Board to be reduced from seven to four members and re-election of Mikael Lönn, Kenth Petersson and Lotta Ljungqvist. 

 

Genovis’ Nomination Committee:

Mikael Lönn (Chairman)

TIN Fonder, represented by Erik Sprinchorn, Portfolio manager

Andra AP-fonden, represented by Johan Sjöström, Portfolio manager

Aktia Fondbolag AB, represented by Markus Lindqvist, Director, Aktia Kapitalförvaltning AB 

 

 

For more information, please contact: Mikael Lönn, Chairman of the Nomination Committee |+46 (0)70-679 13 13| mikael@lonn-ab.se

 

 

Genovis’ business concept is to apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA). Genovis shares are listed on Nasdaq First North Stockholm and Erik Penser Bank is the Company’s Certified Adviser, certifiedadviser@penser.se, T: +46 (0)8-463 83 00.

 

 

 

Release
  • Svenska